These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 19202699)

  • 41. A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents.
    Byrne RA; Mehilli J; Iijima R; Schulz S; Pache J; Seyfarth M; Schömig A; Kastrati A
    Eur Heart J; 2009 Apr; 30(8):923-31. PubMed ID: 19240066
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Introduction to the topic: drug eluting stents. An underestimated problem in surgery].
    Jähne J; Schirren J
    Chirurg; 2009 Jun; 80(6):497. PubMed ID: 19434381
    [No Abstract]   [Full Text] [Related]  

  • 43. Drug-eluting stents for the treatment of coronary artery disease: NICE technology appraisal guidance.
    Messori A; Trippoli S
    Heart; 2009 May; 95(10):847. PubMed ID: 19401286
    [No Abstract]   [Full Text] [Related]  

  • 44. Stent thrombosis aspiration thrombectomy: is this another glimmer of hope?
    Lawson C; Garcia LA
    J Invasive Cardiol; 2009 May; 21(5):214-5. PubMed ID: 19411721
    [No Abstract]   [Full Text] [Related]  

  • 45. Comprehensive meta-analysis on drug-eluting stents versus bare-metal stents during extended follow-up.
    Roukoz H; Bavry AA; Sarkees ML; Mood GR; Kumbhani DJ; Rabbat MG; Bhatt DL
    Am J Med; 2009 Jun; 122(6):581.e1-10. PubMed ID: 19486720
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Endothelial progenitor cell (EPC) capture to aid vascular repair following coronary stenting: a new frontier in stent technology?
    Houtgraaf JH; Duckers HJ
    EuroIntervention; 2008 Aug; 4 Suppl C():C67-71. PubMed ID: 19202700
    [No Abstract]   [Full Text] [Related]  

  • 47. Novel antiplatelet therapies following percutaneous coronary interventions.
    Ahrens I; Bode C
    Curr Opin Investig Drugs; 2009 Sep; 10(9):902-11. PubMed ID: 19705332
    [TBL] [Abstract][Full Text] [Related]  

  • 48. MAHOROBA, first-in-man study: 6-month results of a biodegradable polymer sustained release tacrolimus-eluting stent in de novo coronary stenoses.
    Onuma Y; Serruys P; den Heijer P; Joesoef KS; Duckers H; Regar E; Kukreja N; Tanimoto S; Garcia-Garcia HM; van Beusekom H; van der Giessen W; Nishide T
    Eur Heart J; 2009 Jun; 30(12):1477-85. PubMed ID: 19406868
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Drug-eluting coronary stents and drug eluting balloon catheters: summary of the position papers of the DGK].
    Silber S; Borggrefe M; Böhm M; Hoffmeister HM; Dietz R; Ertl G; Heusch G
    Clin Res Cardiol; 2008 Aug; 97(8):548-63. PubMed ID: 18726643
    [No Abstract]   [Full Text] [Related]  

  • 50. Differences in restenosis rate with different drug-eluting stents in patients with and without diabetes mellitus: a report from the SCAAR (Swedish Angiography and Angioplasty Registry).
    Fröbert O; Lagerqvist B; Carlsson J; Lindbäck J; Stenestrand U; James SK
    J Am Coll Cardiol; 2009 May; 53(18):1660-7. PubMed ID: 19406341
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Surface material, surface treatment and nanotechnology in cardiovascular stent development.
    Sprague EA; Pomeranz ML; Odess I; Furnish SM; Granada JF
    EuroIntervention; 2008 Aug; 4 Suppl C():C60-2. PubMed ID: 19202698
    [No Abstract]   [Full Text] [Related]  

  • 52. NICE guidelines for the use of drug-eluting stents: how do we establish worth?
    de Belder MA;
    Heart; 2008 Dec; 94(12):1646-8. PubMed ID: 18728067
    [No Abstract]   [Full Text] [Related]  

  • 53. Commentary on drug-eluting stents: NICE technology appraisal guidance.
    Richardson J; Stevens A; Barnett D; Longson C
    Heart; 2008 Dec; 94(12):1650-2. PubMed ID: 18768567
    [No Abstract]   [Full Text] [Related]  

  • 54. Commentary on drug-eluting stents: to use or not to use--that is the question!
    Pfisterer ME
    Heart; 2008 Dec; 94(12):1648-50. PubMed ID: 18782796
    [No Abstract]   [Full Text] [Related]  

  • 55. Myocardial Bridge in association with fixed atherosclerotic lesions treated with drug-eluting stents: a follow-up report with quantitative coronary analysis.
    Arora P; Bhatia V; Parida AK; Kaul U
    Indian Heart J; 2008; 60(6):594-6. PubMed ID: 19276504
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Getting real with drug-eluting stents: 5-year follow up of a real-world cohort.
    Sakhuja R; Bhatt DL
    Am Heart J; 2009 May; 157(5):802-4. PubMed ID: 19376303
    [No Abstract]   [Full Text] [Related]  

  • 57. Neointimal regression-induced incomplete coverage of a bare-metal stent in the left main trunk: serial angiographic and angioscopic evidence obtained by 5-year follow-up.
    Ichikawa M; Mishima M
    Catheter Cardiovasc Interv; 2009 May; 73(6):787-90. PubMed ID: 19309734
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction.
    Lee CW; Park DW; Lee SH; Kim YH; Hong MK; Kim JJ; Park SW; Yun SC; Seong IW; Lee JH; Lee NH; Cho YH; Cheong SS; Lim DS; Yang JY; Lee SG; Kim KS; Yoon J; Jeong MH; Seung KB; Hong TJ; Park SJ;
    Am J Cardiol; 2009 Nov; 104(10):1370-6. PubMed ID: 19892052
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Secondary revascularisation following intracoronary brachytherapy.
    Sabaté M
    EuroIntervention; 2009 May; 5 Suppl D():D121-6. PubMed ID: 19736060
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of drug-eluting stents and coronary artery bypass surgery for the treatment of multivessel coronary disease: three-year follow-up results from a single institution.
    Li Y; Zheng Z; Xu B; Zhang S; Li W; Gao R; Hu S
    Circulation; 2009 Apr; 119(15):2040-50. PubMed ID: 19349321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.